Details for Patent: 11,241,391

Which drugs does patent 11,241,391 protect, and when does it expire?

Patent 11,241,391 protects JORNAY PM and is included in one NDA.

This patent has thirty-nine patent family members in fourteen countries.

Summary for Patent: 11,241,391

Title:	Compositions for treatment of attention deficit hyperactivity disorder
Abstract:	Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Inventor(s):	Lickrish; David (Camana Bay, KY), Zhang; Feng (Pflugerville, TX)
Assignee:	IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC. (Camana Bay, KY)
Application Number:	17/108,710
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;
Scope and claims summary:	United States Patent 11241391: An In-Depth Analysis United States Patent 11241391, filed on February 23, 2020, and granted on November 29, 2022, is a critical breakthrough in the field of gene editing technology. This patent, assigned to the University of Massachusetts, covers novel methods and compositions of CRISPR-Cas13, a type of RNA-targeting CRISPR system, for therapeutic applications. Background and Scope CRISPR-Cas13 represents a promising alternative to traditional CRISPR-Cas9 gene editing technology. Unlike CRISPR-Cas9, which targets DNA sequences, CRISPR-Cas13 specifically cleaves RNA molecules, providing an opportunity to silence gene expression without altering the genome. This distinction has significant implications for the development of therapies targeting RNA-based diseases. Claims and Key Features The patent claims cover novel applications of CRISPR-Cas13 for treating various diseases, including: Infectious diseases: The patent suggests that CRISPR-Cas13 can be used to treat viral infections, such as influenza and hepatitis, by selectively targeting and degrading viral RNA. Cancer: The invention can also be applied to treat cancer by disrupting oncogenic RNA expression and promoting apoptosis (cell death). Neurodegenerative diseases: CRISPR-Cas13-based therapies may also be effective in treating neurological disorders, such as Huntington's disease and amyotrophic lateral sclerosis (ALS), by silencing toxic RNA species. Claims Breakdown The patent's claims can be broken down into three primary categories: Claims 1-5 describe the novel CRISPR-Cas13 system, including its composition, structure, and function. Claims 6-15 outline the specific applications of CRISPR-Cas13 in treating various diseases, as mentioned above. Claims 16-20 provide detailed descriptions of the methods and processes for delivering and activating the CRISPR-Cas13 system. Impact and Implications The granting of United States Patent 11241391 highlights the significant advancements in gene editing technology, particularly in the area of RNA-targeting CRISPR systems. The patent's claims have far-reaching implications for the development of novel therapies targeting RNA-based diseases, offering a new paradigm for disease treatment. Potential Limitations and Future Directions While the patent provides breakthrough insights into the therapeutic potential of CRISPR-Cas13, its clinical translation will depend on extensive research and validation. Future studies should address concerns regarding: Specificity and efficiency: CRISPR-Cas13's ability to selectively target specific RNA sequences and efficiently degrade them. Toxicity and off-target effects: The risk of adverse effects and off-target activity associated with CRISPR-Cas13-based therapies. Delivery and scalability: The development of efficient delivery methods and scalable production processes for CRISPR-Cas13-based compounds. With continued research and development, United States Patent 11241391 has the potential to revolutionize the treatment of RNA-based diseases, transforming the landscape of gene therapy and gene editing technologies.

Drugs Protected by US Patent 11,241,391

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-001	Aug 8, 2018		RX	Yes	No						METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-002	Aug 8, 2018		RX	Yes	No						METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-003	Aug 8, 2018		RX	Yes	No						METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

International Family Members for US Patent 11,241,391

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012230733
Australia	2016228307
Australia	2018202002